Cargando…
Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data
BACKGROUND: From March to April 2020, Spain was the center of the SARS-CoV-2 pandemic, particularly Madrid with approximately 30% of the cases in Spain. The aim of this study is to report the suspected serious adverse drug reactions (SADRs) in COVID-19 patients vs. non-COVID-19 patients detected by...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744878/ https://www.ncbi.nlm.nih.gov/pubmed/33343374 http://dx.doi.org/10.3389/fphar.2020.602841 |
_version_ | 1783624508871016448 |
---|---|
author | Ramírez, Elena Urroz, Mikel Rodríguez, Amelia González-Muñoz, Miguel Martín-Vega, Alberto Villán, Yuri Seco, Enrique Monserrat, Jaime Frías, Jesús Carcas, Antonio J. Borobia, Alberto M. |
author_facet | Ramírez, Elena Urroz, Mikel Rodríguez, Amelia González-Muñoz, Miguel Martín-Vega, Alberto Villán, Yuri Seco, Enrique Monserrat, Jaime Frías, Jesús Carcas, Antonio J. Borobia, Alberto M. |
author_sort | Ramírez, Elena |
collection | PubMed |
description | BACKGROUND: From March to April 2020, Spain was the center of the SARS-CoV-2 pandemic, particularly Madrid with approximately 30% of the cases in Spain. The aim of this study is to report the suspected serious adverse drug reactions (SADRs) in COVID-19 patients vs. non-COVID-19 patients detected by the prospective pharmacovigilance program based on automatic laboratory signals (ALSs) in the hospital (PPLSH) during that period. We also compared the results with the suspected SADRs detected during the same period for 2019. METHODS: All ALSs that reflected potential SADRs including neutropenia, pancytopenia, thrombocytopenia, anemia, eosinophilia, leukocytes in cerebrospinal fluid, hepatitis, pancreatitis, acute kidney injury, rhabdomyolysis, and hyponatremia were prospectively monitored in hospitalized patients during the study periods. We analyzed the incidence and the distribution of causative drugs for the COVID-19 patients. RESULTS: The incidence rate of SADRs detected in the COVID-19 patients was 760.63 (95% CI 707.89–816.01) per 10,000 patients, 4.75-fold higher than the SADR rate for non-COVID-19 patients (160.15 per 10,000 patients, 95% CI 137.09–186.80), and 5.84-fold higher than the SADR rate detected for the same period in 2019 (130.19 per 10,000 patients, 95% CI 109.53–154.36). The most frequently related drugs were tocilizumab (59.84%), dexketoprofen (13.93%), azithromycin (8.43%), lopinavir-ritonavir (7.35%), dexamethasone (7.62%), and chloroquine/hydroxychloroquine (6.91%). CONCLUSIONS: The incidence rate of SADRs detected by the PPSLH in patients with COVID-19 was 4.75-fold higher than that of the non-COVID-19 patients. Caution is recommended when using medications for COVID-19 patients, especially drugs that are hepatotoxic, myotoxic, and those that induce thromboembolic events. |
format | Online Article Text |
id | pubmed-7744878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77448782020-12-18 Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data Ramírez, Elena Urroz, Mikel Rodríguez, Amelia González-Muñoz, Miguel Martín-Vega, Alberto Villán, Yuri Seco, Enrique Monserrat, Jaime Frías, Jesús Carcas, Antonio J. Borobia, Alberto M. Front Pharmacol Pharmacology BACKGROUND: From March to April 2020, Spain was the center of the SARS-CoV-2 pandemic, particularly Madrid with approximately 30% of the cases in Spain. The aim of this study is to report the suspected serious adverse drug reactions (SADRs) in COVID-19 patients vs. non-COVID-19 patients detected by the prospective pharmacovigilance program based on automatic laboratory signals (ALSs) in the hospital (PPLSH) during that period. We also compared the results with the suspected SADRs detected during the same period for 2019. METHODS: All ALSs that reflected potential SADRs including neutropenia, pancytopenia, thrombocytopenia, anemia, eosinophilia, leukocytes in cerebrospinal fluid, hepatitis, pancreatitis, acute kidney injury, rhabdomyolysis, and hyponatremia were prospectively monitored in hospitalized patients during the study periods. We analyzed the incidence and the distribution of causative drugs for the COVID-19 patients. RESULTS: The incidence rate of SADRs detected in the COVID-19 patients was 760.63 (95% CI 707.89–816.01) per 10,000 patients, 4.75-fold higher than the SADR rate for non-COVID-19 patients (160.15 per 10,000 patients, 95% CI 137.09–186.80), and 5.84-fold higher than the SADR rate detected for the same period in 2019 (130.19 per 10,000 patients, 95% CI 109.53–154.36). The most frequently related drugs were tocilizumab (59.84%), dexketoprofen (13.93%), azithromycin (8.43%), lopinavir-ritonavir (7.35%), dexamethasone (7.62%), and chloroquine/hydroxychloroquine (6.91%). CONCLUSIONS: The incidence rate of SADRs detected by the PPSLH in patients with COVID-19 was 4.75-fold higher than that of the non-COVID-19 patients. Caution is recommended when using medications for COVID-19 patients, especially drugs that are hepatotoxic, myotoxic, and those that induce thromboembolic events. Frontiers Media S.A. 2020-12-03 /pmc/articles/PMC7744878/ /pubmed/33343374 http://dx.doi.org/10.3389/fphar.2020.602841 Text en Copyright © 2020 Ramírez, Urroz, Rodríguez, González‐Muñoz, MartínVega, Villán, Seco, Monserrat, Frías, Carcas and Borobia http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ramírez, Elena Urroz, Mikel Rodríguez, Amelia González-Muñoz, Miguel Martín-Vega, Alberto Villán, Yuri Seco, Enrique Monserrat, Jaime Frías, Jesús Carcas, Antonio J. Borobia, Alberto M. Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data |
title | Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data |
title_full | Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data |
title_fullStr | Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data |
title_full_unstemmed | Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data |
title_short | Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data |
title_sort | incidence of suspected serious adverse drug reactions in corona virus disease-19 patients detected by a pharmacovigilance program by laboratory signals in a tertiary hospital in spain: cautionary data |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744878/ https://www.ncbi.nlm.nih.gov/pubmed/33343374 http://dx.doi.org/10.3389/fphar.2020.602841 |
work_keys_str_mv | AT ramirezelena incidenceofsuspectedseriousadversedrugreactionsincoronavirusdisease19patientsdetectedbyapharmacovigilanceprogrambylaboratorysignalsinatertiaryhospitalinspaincautionarydata AT urrozmikel incidenceofsuspectedseriousadversedrugreactionsincoronavirusdisease19patientsdetectedbyapharmacovigilanceprogrambylaboratorysignalsinatertiaryhospitalinspaincautionarydata AT rodriguezamelia incidenceofsuspectedseriousadversedrugreactionsincoronavirusdisease19patientsdetectedbyapharmacovigilanceprogrambylaboratorysignalsinatertiaryhospitalinspaincautionarydata AT gonzalezmunozmiguel incidenceofsuspectedseriousadversedrugreactionsincoronavirusdisease19patientsdetectedbyapharmacovigilanceprogrambylaboratorysignalsinatertiaryhospitalinspaincautionarydata AT martinvegaalberto incidenceofsuspectedseriousadversedrugreactionsincoronavirusdisease19patientsdetectedbyapharmacovigilanceprogrambylaboratorysignalsinatertiaryhospitalinspaincautionarydata AT villanyuri incidenceofsuspectedseriousadversedrugreactionsincoronavirusdisease19patientsdetectedbyapharmacovigilanceprogrambylaboratorysignalsinatertiaryhospitalinspaincautionarydata AT secoenrique incidenceofsuspectedseriousadversedrugreactionsincoronavirusdisease19patientsdetectedbyapharmacovigilanceprogrambylaboratorysignalsinatertiaryhospitalinspaincautionarydata AT monserratjaime incidenceofsuspectedseriousadversedrugreactionsincoronavirusdisease19patientsdetectedbyapharmacovigilanceprogrambylaboratorysignalsinatertiaryhospitalinspaincautionarydata AT friasjesus incidenceofsuspectedseriousadversedrugreactionsincoronavirusdisease19patientsdetectedbyapharmacovigilanceprogrambylaboratorysignalsinatertiaryhospitalinspaincautionarydata AT carcasantonioj incidenceofsuspectedseriousadversedrugreactionsincoronavirusdisease19patientsdetectedbyapharmacovigilanceprogrambylaboratorysignalsinatertiaryhospitalinspaincautionarydata AT borobiaalbertom incidenceofsuspectedseriousadversedrugreactionsincoronavirusdisease19patientsdetectedbyapharmacovigilanceprogrambylaboratorysignalsinatertiaryhospitalinspaincautionarydata |